ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for IMVT

Stock NameImmunovant Inc
TickerIMVT(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS45258J1025

Show aggregate IMVT holdings

News associated with IMVT

Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the […] - 2025-08-26 04:26:49
Bank of America Lowers Immunovant (NASDAQ:IMVT) Price Target to $30.00
Immunovant (NASDAQ:IMVT – Get Free Report) had its price objective reduced by equities research analysts at Bank of America from $33.00 to $30.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price objective would suggest a potential upside of 88.80% from the stock’s […] - 2025-08-14 03:07:05
Immunovant Posts 34% R&D Jump in Q1
Key Points- Immunovant’s net loss widened to $0.71 per share (GAAP) in Q1 FY2026 as expenses rose with pipeline expansion. - 2025-08-11 08:27:59
Immunovant, Inc. (NASDAQ:IMVT) Receives $36.40 Average Price Target from Analysts
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the […] - 2025-08-04 02:42:53
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $38.33
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The […] - 2025-07-10 02:50:51
Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of “Moderate Buy” from Brokerages
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the […] - 2025-06-12 05:18:48
How The Pieces Add Up: SCHK Headed For $32
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-05 07:23:06
ProShare Advisors LLC Buys 3,681 Shares of Immunovant, Inc. (NASDAQ:IMVT)
ProShare Advisors LLC boosted its position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 23,300 shares of the company’s stock after purchasing an additional 3,681 shares during the period. ProShare Advisors LLC’s holdings in Immunovant were worth $577,000 as of its most recent filing […] - 2025-05-26 05:18:59
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of “Moderate Buy” from Brokerages
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been given a consensus rating of “Moderate Buy” by the ten ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-05-23 05:00:51
Immunovant, Inc. (NASDAQ:IMVT) Shares Purchased by D. E. Shaw & Co. Inc.
D. E. Shaw & Co. Inc. increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 8.4% in the fourth quarter, Holdings Channel reports. The firm owned 67,669 shares of the company’s stock after buying an additional 5,234 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Immunovant were […] - 2025-05-22 04:48:46
The Manufacturers Life Insurance Company Sells 772 Shares of Immunovant, Inc. (NASDAQ:IMVT)
The Manufacturers Life Insurance Company lowered its stake in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 2.1% during the fourth quarter, HoldingsChannel reports. The firm owned 35,908 shares of the company’s stock after selling 772 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Immunovant were worth $889,000 as of its […] - 2025-05-15 04:45:06
Invesco Ltd. Lowers Holdings in Immunovant, Inc. (NASDAQ:IMVT)
Invesco Ltd. reduced its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 15.2% in the fourth quarter, Holdings Channel reports. The firm owned 504,032 shares of the company’s stock after selling 90,210 shares during the period. Invesco Ltd.’s holdings in Immunovant were worth $12,485,000 at the end of the most recent reporting […] - 2025-04-22 04:57:06
Geode Capital Management LLC Purchases 4,094 Shares of Immunovant, Inc. (NASDAQ:IMVT)
Geode Capital Management LLC grew its position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 0.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,515,020 shares of the company’s stock after acquiring an additional 4,094 shares during the quarter. Geode […] - 2025-04-16 04:39:00
Norges Bank Buys Shares of 637,947 Immunovant, Inc. (NASDAQ:IMVT)
Norges Bank purchased a new position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 637,947 shares of the company’s stock, valued at approximately $15,802,000. A number of other large investors have also […] - 2025-04-08 04:46:59
Peek Under The Hood: DFAC Has 28% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-04 08:47:40
Teacher Retirement System of Texas Acquires 2,373 Shares of Immunovant, Inc. (NASDAQ:IMVT)
Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,203 shares of the company’s stock after acquiring an additional 2,373 shares during the quarter. […] - 2025-04-01 04:44:44
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $41.00
Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been given a consensus recommendation of “Buy” by the ten analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the […] - 2025-04-01 02:40:43
HC Wainwright Reiterates “Buy” Rating for Immunovant (NASDAQ:IMVT)
Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $51.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 159.01% from the company’s previous close. Several other […] - 2025-03-21 04:42:50
Guggenheim Reaffirms Buy Rating for Immunovant (NASDAQ:IMVT)
Guggenheim reiterated their buy rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a report issued on Monday morning,Benzinga reports. A number of other brokerages have also issued reports on IMVT. Cantor Fitzgerald upgraded shares of Immunovant to a “strong-buy” rating in a research report on Tuesday, March 4th. Jefferies Financial Group assumed coverage […] - 2025-03-11 04:40:47
Immunovant, Inc. (NASDAQ:IMVT) Receives $43.55 Consensus Target Price from Analysts
Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have received an average recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy […] - 2025-03-07 04:43:06
Immunovant (NASDAQ:IMVT) Coverage Initiated at Jefferies Financial Group
Equities researchers at Jefferies Financial Group began coverage on shares of Immunovant (NASDAQ:IMVT – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage set a “hold” rating and a $20.00 price target on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 8.17% […] - 2025-03-05 05:04:58
Comparing Immunovant (NASDAQ:IMVT) & OKYO Pharma (NASDAQ:OKYO)
Immunovant (NASDAQ:IMVT – Get Free Report) and OKYO Pharma (NASDAQ:OKYO – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Profitability This table compares Immunovant and OKYO Pharma’s net […] - 2025-03-05 04:20:53
Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Principal Financial Group Inc.
Principal Financial Group Inc. trimmed its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 16.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 791,863 shares of the company’s stock after selling 159,261 shares during the quarter. Principal Financial Group Inc.’s holdings in Immunovant were worth $19,614,000 as of its most recent […] - 2025-02-25 06:48:54
Guggenheim Cuts Immunovant (NASDAQ:IMVT) Price Target to $44.00
Immunovant (NASDAQ:IMVT – Get Free Report) had its price target dropped by equities researchers at Guggenheim from $46.00 to $44.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 127.51% from the company’s […] - 2025-02-12 06:46:57
Immunovant, Inc. (NASDAQ:IMVT) Receives $47.00 Consensus PT from Brokerages
Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been assigned an average recommendation of “Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating […] - 2025-02-12 06:09:06
Immunovant (NASDAQ:IMVT) Sets New 1-Year Low on Disappointing Earnings
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) shares hit a new 52-week low during trading on Monday following a weaker than expected earnings announcement. The stock traded as low as $19.82 and last traded at $19.60, with a volume of 702620 shares trading hands. The stock had previously closed at $20.41. The company reported ($0.76) […] - 2025-02-12 04:14:58
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by KBC Group NV
KBC Group NV boosted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 60.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,099 shares of the company’s stock after buying an additional 1,163 shares during the quarter. KBC Group NV’s […] - 2025-02-10 16:30:58

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc IMVT holdings

DateNumber of IMVT Shares HeldBase Market Value of IMVT SharesLocal Market Value of IMVT SharesChange in IMVT Shares HeldChange in IMVT Base ValueCurrent Price per IMVT Share HeldPrevious Price per IMVT Share Held
2025-12-11 (Thursday)9,076USD 225,176IMVT holding increased by 11345USD 225,1760USD 11,345 USD 24.81 USD 23.56
2025-12-10 (Wednesday)9,076USD 213,831IMVT holding increased by 7261USD 213,8310USD 7,261 USD 23.56 USD 22.76
2025-12-09 (Tuesday)9,076USD 206,570IMVT holding decreased by -3721USD 206,5700USD -3,721 USD 22.76 USD 23.17
2025-12-08 (Monday)9,076USD 210,291IMVT holding increased by 2995USD 210,2910USD 2,995 USD 23.17 USD 22.84
2025-12-05 (Friday)9,076USD 207,296IMVT holding decreased by -635USD 207,2960USD -635 USD 22.84 USD 22.91
2025-12-04 (Thursday)9,076USD 207,931IMVT holding increased by 1815USD 207,9310USD 1,815 USD 22.91 USD 22.71
2025-12-03 (Wednesday)9,076IMVT holding decreased by -155USD 206,116IMVT holding increased by 2849USD 206,116-155USD 2,849 USD 22.71 USD 22.02
2025-12-02 (Tuesday)9,231IMVT holding increased by 62USD 203,267IMVT holding decreased by -5328USD 203,26762USD -5,328 USD 22.02 USD 22.75
2025-12-01 (Monday)9,169USD 208,595IMVT holding decreased by -12836USD 208,5950USD -12,836 USD 22.75 USD 24.15
2025-11-28 (Friday)9,169USD 221,431IMVT holding increased by 4126USD 221,4310USD 4,126 USD 24.15 USD 23.7
2025-11-27 (Thursday)9,169USD 217,305USD 217,3050USD 0 USD 23.7 USD 23.7
2025-11-26 (Wednesday)9,169USD 217,305IMVT holding decreased by -2293USD 217,3050USD -2,293 USD 23.7 USD 23.95
2025-11-25 (Tuesday)9,169IMVT holding decreased by -93USD 219,598IMVT holding increased by 3608USD 219,598-93USD 3,608 USD 23.95 USD 23.32
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of IMVT by Blackrock for IE00B3VWM098

Show aggregate share trades of IMVT

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-12-03SELL-15523.06022.100 22.196USD -3,440 19.88 Loss of -359 on sale
2025-12-02BUY6223.05521.930 22.043USD 1,367 19.87
2025-11-25SELL-9324.07023.000 23.107USD -2,149 19.78 Loss of -310 on sale
2025-11-24SELL-9323.45022.430 22.532USD -2,095 19.76 Loss of -258 on sale
2025-11-17SELL-34124.73023.500 23.623USD -8,055 19.67 Loss of -1,347 on sale
2025-11-12SELL-3124.10022.600 22.750USD -705 19.62 Loss of -97 on sale
2025-11-06SELL-3124.27023.400 23.487USD -728 19.54 Loss of -122 on sale
2025-11-05SELL-31024.29523.370 23.463USD -7,273 19.52 Loss of -1,223 on sale
2025-11-04SELL-6224.53023.310 23.432USD -1,453 19.49 Loss of -244 on sale
2025-11-03SELL-6225.17023.710 23.856USD -1,479 19.47 Loss of -272 on sale
2025-10-28BUY9321.98022.000 21.998USD 2,046 19.39
2025-10-24SELL-3118.94019.010 19.003USD -589 19.38 Profit of 12 on sale
2025-10-15BUY18617.93018.065 18.052USD 3,358 19.42
2025-10-02BUY3116.73016.850 16.838USD 522 19.45
2025-09-30BUY6216.12016.170 16.165USD 1,002 19.48
2025-08-21SELL-5414.84014.890 14.885USD -804 19.60 Profit of 255 on sale
2025-07-31BUY16216.08016.665 16.607USD 2,690 19.65
2025-06-30SELL-10816.00016.340 16.306USD -1,761 19.96 Profit of 395 on sale
2025-06-25SELL-5415.75016.000 15.975USD -863 20.04 Profit of 220 on sale
2025-06-20SELL-10815.80016.040 16.016USD -1,730 20.14 Profit of 445 on sale
2025-05-23BUY5414.46014.475 14.474USD 782 20.91
2025-05-19SELL-5414.70014.790 14.781USD -798 21.13 Profit of 343 on sale
2025-05-15SELL-16213.92014.003 13.995USD -2,267 21.25 Profit of 1,176 on sale
2025-05-12SELL-5414.55015.170 15.108USD -816 21.44 Profit of 342 on sale
2025-05-09SELL-5414.02014.705 14.636USD -790 21.51 Profit of 371 on sale
2025-04-30SELL-5416.15016.405 16.380USD -884 21.95 Profit of 301 on sale
2025-04-24SELL-10815.07015.105 15.101USD -1,631 22.23 Profit of 770 on sale
2025-04-17SELL-5415.15015.250 15.240USD -823 22.63 Profit of 399 on sale
2025-04-15SELL-16215.46515.760 15.731USD -2,548 22.79 Profit of 1,144 on sale
2025-04-14SELL-16215.43015.640 15.619USD -2,530 22.87 Profit of 1,175 on sale
2025-04-09SELL-21614.90015.040 15.026USD -3,246 23.15 Profit of 1,755 on sale
2025-04-07SELL-37814.39015.290 15.200USD -5,746 23.37 Profit of 3,087 on sale
2025-04-04SELL-54014.58015.670 15.561USD -8,403 23.47 Profit of 4,270 on sale
2025-03-31BUY5417.09017.810 17.738USD 958 23.73
2025-03-19SELL-10818.88020.440 20.284USD -2,191 24.26 Profit of 429 on sale
2025-03-14SELL-32419.52019.520 19.520USD -6,324 24.46 Profit of 1,602 on sale
2025-03-13SELL-10818.79019.600 19.519USD -2,108 24.55 Profit of 543 on sale
2025-03-12SELL-1,83619.12019.830 19.759USD -36,278 24.62 Profit of 8,931 on sale
2025-03-07SELL-10820.02020.030 20.029USD -2,163 24.83 Profit of 519 on sale
2025-03-06SELL-16219.52019.880 19.844USD -3,215 24.92 Profit of 822 on sale
2025-03-03SELL-5418.44020.690 20.465USD -1,105 25.21 Profit of 256 on sale
2025-02-28SELL-32420.60020.800 20.780USD -6,733 25.29 Profit of 1,461 on sale
2025-02-26SELL-5420.08020.580 20.530USD -1,109 25.46 Profit of 266 on sale
2025-02-25SELL-16219.78020.630 20.545USD -3,328 25.56 Profit of 813 on sale
2025-02-18BUY27020.82021.430 21.369USD 5,770 26.01
2025-02-13BUY5419.86020.040 20.022USD 1,081 26.36
2025-02-12BUY5419.22019.570 19.535USD 1,055 26.51
2025-02-11BUY16219.34020.185 20.100USD 3,256 26.66
2025-02-06BUY48620.36023.105 22.830USD 11,096 27.10
2025-01-27BUY5422.40023.590 23.471USD 1,267 28.25
2024-12-30BUY27023.88024.551 24.484USD 6,611 28.78
2024-12-06BUY21628.62029.200 29.142USD 6,295 28.78
2024-12-05BUY5428.40028.621 28.599USD 1,544 28.79
2024-12-04BUY27028.52028.980 28.934USD 7,812 28.80
2024-11-29BUY27028.20028.978 28.900USD 7,803 28.85
2024-11-27BUY21628.73029.100 29.063USD 6,278 28.86
2024-11-26BUY5427.16027.390 27.367USD 1,478 28.94
2024-11-21BUY27026.54026.780 26.756USD 7,224 29.28
2024-11-20BUY16226.17026.220 26.215USD 4,247 29.45
2024-11-18BUY64825.51027.000 26.851USD 17,399 29.96
2024-11-12BUY43229.27031.180 30.989USD 13,387 30.01
2024-11-08BUY27030.65031.260 31.199USD 8,424 29.96
2024-11-07BUY81029.93031.660 31.487USD 25,504 29.96
2024-11-06BUY10831.42032.100 32.032USD 3,459 29.84
2024-10-31BUY5429.26030.300 30.196USD 1,631 29.97
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of IMVT

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19237,7710521,18745.6%
2025-09-18226,7750506,19044.8%
2025-09-17318,3080572,77755.6%
2025-09-16284,0180524,50154.2%
2025-09-15298,530184553,28854.0%
2025-09-12266,121411919,71628.9%
2025-09-11239,3078,320608,14639.4%
2025-09-10226,067533740,81730.5%
2025-09-09206,0130593,07034.7%
2025-09-08386,7590554,65269.7%
2025-09-05275,6175,000968,66028.5%
2025-09-04462,8424,880766,80760.4%
2025-09-031,074,12922,3702,021,54153.1%
2025-09-02219,6990617,99135.6%
2025-08-29104,2500282,35436.9%
2025-08-2883,203190219,04438.0%
2025-08-27117,872143563,63420.9%
2025-08-2686,1250351,03824.5%
2025-08-25114,2420393,22629.1%
2025-08-2281,7230567,87114.4%
2025-08-2186,3920519,86616.6%
2025-08-20107,531100642,29216.7%
2025-08-19105,4900456,26723.1%
2025-08-18105,745501404,90226.1%
2025-08-1595,3841,2001,001,4839.5%
2025-08-14106,2160467,02822.7%
2025-08-13157,4183,846443,39135.5%
2025-08-12351,3060413,33385.0%
2025-08-11264,0540468,92256.3%
2025-08-08166,099324243,99068.1%
2025-08-07103,5728177,67258.3%
2025-08-06171,45566250,71868.4%
2025-08-05174,5690295,99759.0%
2025-08-04125,8140208,57060.3%
2025-08-01325,671223565,81357.6%
2025-07-31182,552213394,83346.2%
2025-07-30199,3310404,85449.2%
2025-07-29186,8646,654505,16737.0%
2025-07-28242,81016,158605,00840.1%
2025-07-25729,81311,6591,679,63743.5%
2025-07-24226,01538,604388,76158.1%
2025-07-23284,30969,677444,14764.0%
2025-07-22160,56033,025259,86261.8%
2025-07-21130,7730240,83454.3%
2025-07-18169,6090264,61964.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy